Axsome Therapeutics, Inc. (AXSM): Price and Financial Metrics

Axsome Therapeutics, Inc. (AXSM): $65.91

-0.63 (-0.95%)

POWR Rating

Component Grades













AXSM Stock Price Chart Interactive Chart >

Price chart for AXSM

AXSM Price/Volume Stats

Current price $65.91 52-week high $90.00
Prev. close $66.54 52-week low $50.05
Day low $65.20 Volume 175,756
Day high $66.65 Avg. volume 340,390
50-day MA $58.70 Dividend yield N/A
200-day MA $69.04 Market Cap 2.48B

Axsome Therapeutics, Inc. (AXSM) Company Bio

Axsome Therapeutics Inc. focuses on developing therapies for the management of pain, neurological disorders, and other central nervous system. The company was founded in 2012 and is based in New York City, New York.

AXSM Latest News Stream

Event/Time News Detail
Loading, please wait...

AXSM Latest Social Stream

Loading social stream, please wait...

View Full AXSM Social Stream

Latest AXSM News From Around the Web

Below are the latest news stories about Axsome Therapeutics Inc that investors may wish to consider to help them evaluate AXSM as an investment opportunity.

Axsome (AXSM) Plans NDA Filing for Fibromyalgia Drug in 2022

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.

Yahoo | June 16, 2021

Axsome Therapeutics Targets Submission Of US Application For Fibromyalgia Candidate By 2022

After a pre-NDA meeting with FDA, Axsome Therapeutics Inc (NASDAQ: AXSM) has announced its plan to submit a marketing application seeking approval for AXS-14 to manage fibromyalgia. The submission is currently anticipated in the fourth quarter of 2022, pending completion of manufacturing and other activities related to the product candidate. AXS-14 has completed two positive placebo-controlled trials, a Phase 3 and a Phase 2 trial, which will be included in the submission. Fibromyalgia is a chro

Yahoo | June 15, 2021

Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia

Submission anticipated in 4Q 2022 NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced its plan to submit a New Drug Application (NDA) for AXS-14 for the management of fibromyalgia following a pre-NDA meeting with the U.S. Food and Drug Administration (FDA). AXS-14 (esreboxetine) is a novel, oral, potent, and highly selective norepi

Yahoo | June 15, 2021

Why Is Axsome (AXSM) Up 14.7% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | June 9, 2021

2 Top Biotech Stocks to Buy for Summer 2021

Progress in these companies' drug development pipelines should give shareholders plenty to look forward to.

Yahoo | June 5, 2021

Read More 'AXSM' Stories Here

AXSM Price Returns

1-mo 18.65%
3-mo 2.03%
6-mo -15.79%
1-year -14.83%
3-year 2,097.00%
5-year 939.59%
YTD -19.10%
2020 -21.18%
2019 3,565.25%
2018 -49.64%
2017 -17.04%
2016 -27.18%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8002 seconds.